Expert Ratings For Pacira BioSciences
Portfolio Pulse from Benzinga Insights
Pacira BioSciences (NASDAQ:PCRX) has been analyzed by 8 analysts in the last three months, showing a range of ratings from bullish to bearish. The average 12-month price target has decreased by 8.72% to $41.88. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance.
July 25, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Pacira BioSciences has received mixed analyst ratings over the past three months, with a notable decrease in the average 12-month price target from $45.88 to $41.88. Analysts have adjusted their ratings and price targets, reflecting their response to recent developments related to the company.
The mixed analyst ratings and the decrease in the average 12-month price target indicate a neutral short-term impact on the stock price. While some analysts remain bullish, others have lowered their ratings and price targets, reflecting uncertainty and varied expectations about the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100